JP2016520531A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520531A5
JP2016520531A5 JP2016503332A JP2016503332A JP2016520531A5 JP 2016520531 A5 JP2016520531 A5 JP 2016520531A5 JP 2016503332 A JP2016503332 A JP 2016503332A JP 2016503332 A JP2016503332 A JP 2016503332A JP 2016520531 A5 JP2016520531 A5 JP 2016520531A5
Authority
JP
Japan
Prior art keywords
protein
scgb3a2
recombinant human
homodimer
intact
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520531A (ja
JP6513632B2 (ja
Filing date
Publication date
Priority claimed from US13/843,289 external-priority patent/US20140274915A1/en
Application filed filed Critical
Publication of JP2016520531A publication Critical patent/JP2016520531A/ja
Publication of JP2016520531A5 publication Critical patent/JP2016520531A5/ja
Application granted granted Critical
Publication of JP6513632B2 publication Critical patent/JP6513632B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503332A 2013-03-15 2014-03-16 組換えヒトセクレトグロビンの改善された使用方法 Expired - Fee Related JP6513632B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/843,289 2013-03-15
US13/843,289 US20140274915A1 (en) 2013-03-15 2013-03-15 Methods of Use for Recombinant Human Secretoglobins
PCT/US2014/030101 WO2014145357A2 (en) 2013-03-15 2014-03-16 Improved methods of use for recombinant human secretoglobins

Publications (3)

Publication Number Publication Date
JP2016520531A JP2016520531A (ja) 2016-07-14
JP2016520531A5 true JP2016520531A5 (https=) 2017-04-27
JP6513632B2 JP6513632B2 (ja) 2019-05-15

Family

ID=51529893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503332A Expired - Fee Related JP6513632B2 (ja) 2013-03-15 2014-03-16 組換えヒトセクレトグロビンの改善された使用方法

Country Status (15)

Country Link
US (5) US20140274915A1 (https=)
EP (1) EP2968464B1 (https=)
JP (1) JP6513632B2 (https=)
KR (1) KR20160011621A (https=)
CN (1) CN105722524B (https=)
AU (1) AU2014233116A1 (https=)
BR (1) BR112015021265A2 (https=)
CA (1) CA2907395A1 (https=)
ES (1) ES2883933T3 (https=)
IL (1) IL241418A0 (https=)
MX (1) MX2015013091A (https=)
RU (1) RU2662665C2 (https=)
SG (1) SG11201507276UA (https=)
UA (1) UA118756C2 (https=)
WO (1) WO2014145357A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140274915A1 (en) * 2013-03-15 2014-09-18 Clarassance, Inc. Methods of Use for Recombinant Human Secretoglobins
WO2016205430A1 (en) * 2015-06-15 2016-12-22 Therabron Therapeutics, Inc. Recombinant human cc10 protein facilitates repair and protects against damage to the respiratory epithelium due to exposure to both cigarette and other smoke
WO2018178051A1 (en) * 2017-03-28 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Scgb1a1 polymorphism for the prediction and therapy or prevention of primary graft dysfunction
WO2019143934A1 (en) 2018-01-19 2019-07-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cancer activity of scbg3a2 and lps
JP2022509856A (ja) * 2018-11-30 2022-01-24 エーピーシー リサーチ アセッツ，エルエルシー ヘパラン硫酸プロテオグリカンタンパク質との相互作用を介してグリコカリックスを保護するためのセクレトグロビンの組成物及び使用方法
KR20200138684A (ko) * 2020-11-17 2020-12-10 김유신 토양 파쇄기를 장착한 친환경 고온스팀 토양소독기
WO2023212398A1 (en) * 2022-04-29 2023-11-02 Apc Research Assets Llc Secretoglobins for suppression of antibody responses
CN119631983B (zh) * 2024-12-30 2025-07-22 西南医科大学 一种心脏原发性肿瘤小鼠模型的构建方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030008816A1 (en) 1997-05-28 2003-01-09 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20040047857A1 (en) 1997-05-28 2004-03-11 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20060281681A1 (en) * 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
WO2000009741A1 (en) 1998-08-13 2000-02-24 The Trustees Of The University Of Pennsylvania Method of identifying proteins
US6953666B1 (en) 1998-11-06 2005-10-11 Emory University Biomarkers for oxidative stress
WO2004101824A1 (ja) * 2003-05-14 2004-11-25 Shionogi & Co., Ltd. 慢性閉塞性肺疾患の検出方法
AU2004254600A1 (en) * 2003-06-26 2005-01-13 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
JP2007511517A (ja) 2003-11-14 2007-05-10 アルザ・コーポレーシヨン 薬剤と照射を受けた賦形剤の製剤の中の薬剤の酸化を最小化
US20060275794A1 (en) * 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
JP2007059191A (ja) 2005-08-24 2007-03-08 Kazuo Kono 照明器具駆動回路
US8133859B2 (en) * 2006-09-27 2012-03-13 The United States Of America As Represented By The Department Of Health And Human Services SCGB3A2 as a growth factor and anti-apoptotic agent
US20090004684A1 (en) 2007-05-23 2009-01-01 Claudia Susanne Maier Compositions and Methods for Detection and Quantification of Protein Oxidation
MX2012004409A (es) 2009-10-15 2012-08-23 Clarassance Inc Proteina recombinante de humano cc10 para el tratamiento de la influenza.
RU2439569C1 (ru) * 2010-11-12 2012-01-10 Федеральное государственное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования бронхолегочной дисплазии у детей с врожденной пневмонией
US20140274915A1 (en) * 2013-03-15 2014-09-18 Clarassance, Inc. Methods of Use for Recombinant Human Secretoglobins

Similar Documents

Publication Publication Date Title
JP2016520531A5 (https=)
MX2025003310A (es) Integracion dirigida de acidos nucleicos
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2023007211A (es) Anticuerpos antimiostatina y metodos de uso.
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
PH12020550240A1 (en) D-domain containing polypeptides and uses thereof
AU2017263237A1 (en) GDF15 fusion proteins and uses thereof
MX2017006866A (es) Pares de unión para producción de péptidos.
PH12020550927A1 (en) Therapeutic enzyme fusion protein having novel structure and use thereof
WO2014202616A3 (en) Rasamsonia gene and use thereof
MY181199A (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX382929B (es) Polipéptido heterodimerizado.
MY192481A (en) Factor viii chimeric proteins and uses thereof
MX2017010880A (es) Variantes de polipéptidos para el clivaje de la toxina fusario, aditivo que contiene las mismas, uso de las mismas, y método para el clivaje de las toxinas fusario.
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
MX2017015927A (es) Fragmentos mutantes de proteina ras.
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
SG10201903142RA (en) Serpin fusion polypeptides and methods of use thereof
NZ724196A (en) Uti fusion proteins
WO2016130628A8 (en) Griffithsin mutants
WO2015107363A3 (en) Mycobacterial antigen composition
WO2014170460A3 (en) Method for the production of collagen proteins derived from marine sponges and an organism able to produce said proteins
MX2016007109A (es) Proteina estructurante de hielo.
JP2016519950A5 (https=)